Compare GSHD & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GSHD | INVA |
|---|---|---|
| Founded | 2003 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2018 | 2000 |
| Metric | GSHD | INVA |
|---|---|---|
| Price | $43.64 | $22.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $90.40 | $36.50 |
| AVG Volume (30 Days) | 627.3K | ★ 692.4K |
| Earning Date | 05-20-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 816.67 |
| EPS | 1.04 | ★ 3.30 |
| Revenue | ★ $365,304,000.00 | $217,217,000.00 |
| Revenue This Year | $16.69 | $8.78 |
| Revenue Next Year | $19.77 | $11.99 |
| P/E Ratio | $42.44 | ★ $6.79 |
| Revenue Growth | 16.15 | ★ 62.63 |
| 52 Week Low | $42.87 | $16.52 |
| 52 Week High | $124.40 | $25.15 |
| Indicator | GSHD | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 31.36 | 48.83 |
| Support Level | $42.87 | $19.16 |
| Resistance Level | $77.70 | $22.76 |
| Average True Range (ATR) | 2.50 | 0.69 |
| MACD | -0.10 | -0.21 |
| Stochastic Oscillator | 4.09 | 12.41 |
Goosehead Insurance Inc operates as an insurance agency. Its insurance products consist of homeowner's insurance; auto insurance; other personal lines products including flood, wind and earthquake insurance; excess liability or umbrella insurance; specialty lines insurance (motorcycle, recreational vehicle and other insurance); commercial lines insurance (general liability, property, and auto insurance for small businesses); and life insurance. Geographically, it operates in Texas, California, Illinois, Florida, and other regions.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.